Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance
详细信息 查看全文
- 作者：Petra Becker ; Arnd Schwebig ; Susanne Brauninger ; Heike Bialleck ; Beate Luxembourg ; Miriam Schulz ; Chrysanthi Tsamadou ; Markus Wiesneth ; Peter Reinhardt ; Joannis Mytilineos ; Christian Seidl ; Sreekanth Gattu ; Natalia Kaliakina ; Pritibha Singh ; Hubert Schrezenmeier ; Erhard Seifried and Halvard Bonig
- 刊名：Transfusion
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：56
- 期：12
- 页码：3055-3064
- 全文大小：216K
- ISSN：1537-2995
文摘
Biosimilar granulocyte-colony-stimulating factors (G-CSFs) have been available in the European Union since 2008, and Sandoz' biosimilar filgrastim was approved in the United States in March 2015 for all of the reference product's indications except acute radiation syndrome. Biosimilar G-CSFs have been largely embraced by the medical community, except for some reservations about healthy-donor stem cell mobilization, for which use outside of clinical studies was cautioned against by some members of the scientific community.